Literature DB >> 2088996

Controlled-release morphine bioavailability (MS Contin tablets) in the presence and absence of food.

R F Kaiko, H Lazarus, C Cronin, R Grandy, G Thomas, P Goldenheim.   

Abstract

The bioavailability of a single, orally administered, 30-mg controlled-release morphine tablet (MS Contin Tablet; The Purdue Frederick Company, Norwalk, Conn.) was compared after fasting or a high fat meal in this single dose, randomized, crossover study involving 24 healthy male subjects. There was no significant (p greater than 0.05) difference in the mean extent of morphine absorption over 24 hours in the presence or absence of food (area under the plasma concentration vs. time curve [AUC(0,24)], fed = 107% of fasted). Time to maximal concentration (Tmax) was similar (p greater than 0.05) in the two treatment groups; the mean Tmax for fed volunteers was 2.5 hours versus 2.4 hours for fasted volunteers. The two regimens did not differ significantly (p greater than 0.05) with regard to maximal morphine concentration (Cmax); mean Cmax for fed subjects was 8.22 ng/ml whereas mean Cmax for fasted subjects was 8.53 ng/ It was concluded that consumption of a high fat meal did not affect either the rate or extent of morphine absorption, or any of the other pharmacokinetic parameters tested, following administration of MSC.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2088996     DOI: 10.1080/0742-969x.1990.11882681

Source DB:  PubMed          Journal:  Hosp J        ISSN: 0742-969X


  3 in total

Review 1.  Effects of food on clinical pharmacokinetics.

Authors:  B N Singh
Journal:  Clin Pharmacokinet       Date:  1999-09       Impact factor: 6.447

Review 2.  Sustained relief of chronic pain. Pharmacokinetics of sustained release morphine.

Authors:  G K Gourlay
Journal:  Clin Pharmacokinet       Date:  1998-09       Impact factor: 6.447

3.  Pharmacokinetics and bioavailability of oxycodone and acetaminophen following single-dose administration of MNK-795, a dual-layer biphasic IR/ER combination formulation, under fed and fasted conditions.

Authors:  Krishna Devarakonda; Terri Morton; Rachel Margulis; Michael Giuliani; Thomas Barrett
Journal:  Drug Des Devel Ther       Date:  2014-08-19       Impact factor: 4.162

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.